Asit Pruthi, MD
Ophthalmology · Salinas, CANPI 1770580375
Payments from drug & device makers
What this record shows
Rxsight Inc accounts for 71.0% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $1,285, 7.9 times the $163 reported in 2019.
Across 17 payments — averaging $110.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$1K
- Alcon$313
- Glaukos Corporation$146
- Johnson & Johnson Surgical Vision, Inc.$37
- Sun Pharmaceutical Industries Inc.$17
- Ocular Therapeutix, Inc.$17
- plus $14 from 1 others
What the payments were for
- Consulting fees$1,00053%
- Food & beverage$87347%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rxsight Inc | 8 | $1,329 |
| Alcon | 3 | $313 |
| Glaukos Corporation | 1 | $146 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $37 |
| Sun Pharmaceutical Industries Inc. | 1 | $17 |
| Ocular Therapeutix, Inc. | 1 | $17 |
| Omeros Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,873 in reported general payments places this provider in the 55th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 28 | $32,205 |
| Bromfenac Sodium | 131 | $15,781 |
| Cyclosporine | 20 | $11,126 |
| Prednisolone Acetate | 169 | $9,823 |
| TobradexTobramycin/Dexamethasone | 30 | $7,730 |
| ProlensaBromfenac Sodium | 14 | $4,878 |
| Latanoprost | 164 | $2,250 |
| Timolol Maleate | 36 | $597 |
| ErythromycinErythromycin Base | 41 | $554 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 13 | $145 |
| Carteolol Hcl | 17 | $137 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Salinas
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
- Srinivas SaddaPasadena$1M
- Sheri RowenNewport Beach$1M
- Savak TeymoorianLaguna Hills$955K
- Andrew MoshfeghiLos Angeles$895K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.